Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients

Pharmacogenomics. 2022 Apr;23(5):291-301. doi: 10.2217/pgs-2021-0144. Epub 2022 Feb 11.

Abstract

Background: The aim of this study was to evaluate the association between well-defined genetic risk variants in SLC28A3, RARG and UGT1A6 and anthracycline-induced cardiotoxicity in Mexican pediatric patients. Methods: We tested a cohort of 79 children treated with anthracyclines for the presence of SLC28A3-rs7853758, RARG-rs2229774 and UGT1A6-rs17863783. Results: The SLC28A3-rs7853758 variant was more frequent in this cohort, while the UGT1A6-rs17863783 and RARG-rs2229774 variants were present at lower frequencies. A clinically important decrease of fractional shortening was associated with SLC28A3-rs7853758 variant. Conclusion: In this cohort, 39.2% of patients carried the protective SLC28A3 variant. A small number of tested patients have the risk variants of UGT1A6 and RARG. None of the patients shared the two risk variants.

Keywords: Mexican pediatric patients; RARG; SLC28A3; UGT1A6; anthracycline; cardiotoxicity; fractional shortening; pharmacogenomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracyclines* / adverse effects
  • Antibiotics, Antineoplastic
  • Cardiotoxicity* / genetics
  • Child
  • Humans
  • Pharmacogenomic Testing
  • Risk Factors

Substances

  • Anthracyclines
  • Antibiotics, Antineoplastic